Suppr超能文献

[围手术期抗凝管理]

[Perioperative management of anticoagulation].

作者信息

Eisele R, Melzer N, Bramlage P

机构信息

Abteilung Orthopädie, Unfall- und Wiederherstellungschirurgie, Stiftungsklinik Weißenhorn, Kliniken der Kreisspitalstiftung Weißenhorn, Günzburger Str. 41, 89264, Weißenhorn, Deutschland,

出版信息

Chirurg. 2014 Jun;85(6):513-9. doi: 10.1007/s00104-014-2738-6.

Abstract

BACKGROUND

The aim of the perioperative management of anticoagulation in patients with long-term oral anticoagulation is to minimize bleeding complications of surgical interventions.

OBJECTIVES

We aimed to give a summary of current data and to give practical recommendations for colleagues practicing surgery.

MATERIAL AND METHODS

This article gives a narrative overview of available data from 31 publications between 2000 and 2013.

RESULTS

Every perioperative decision on whether to continue oral anticoagulation is preceded by an assessment of the risk of bleeding and embolism. In cases with a low risk of bleeding, oral anticoagulation can usually be continued. In contrast, for larger interventions with a moderate to high risk of bleeding, a discontinuation of phenprocoumon with temporary bridging is required. In this case it is common practice to discontinue phenprocoumon 7-9 days preoperatively and administer heparin mostly in the form of low molecular weight heparin (LMWH) depending on the international normalized ratio (INR). In contrast perioperative management of direct oral anticoagulants (DOAC) is discussed controversially. Based on the pharmacokinetics of the DAOC, the recommendations are to minimize the anticoagulation-free interval to 2-4 half-lives (HWZ) preoperatively (1-5 days) and early postoperative restart. In this case no bridging is necessary. On the other hand, an early interruption of DOAC 5 days prior to surgery to a minimum of 2 days postoperatively is favored by some surgeons to assure an adequate perioperative hemostasis. Depending on the risk of thromboembolism, bridging is required. These recommendations are justified by limited clinical experience and the absence of antagonism.

CONCLUSION

The perioperative management of coagulation is still a challenge. While there are consolidated decision aids for phenprocoumon, the approach under DOAC treatment is still controversial due to limited data.

摘要

背景

长期口服抗凝剂患者围手术期抗凝管理的目的是将手术干预的出血并发症降至最低。

目的

我们旨在总结当前数据,并为从事外科手术的同事提供实用建议。

材料与方法

本文对2000年至2013年间31篇出版物中的现有数据进行了叙述性综述。

结果

在做出是否继续口服抗凝剂的每一项围手术期决策之前,都要先评估出血和栓塞风险。在出血风险较低的情况下,通常可以继续口服抗凝剂。相比之下,对于出血风险为中度至高度的较大手术,需要停用苯丙香豆素并进行临时桥接。在这种情况下,通常的做法是在术前7 - 9天停用苯丙香豆素,并根据国际标准化比值(INR)主要以低分子量肝素(LMWH)的形式给予肝素。相比之下,直接口服抗凝剂(DOAC)的围手术期管理存在争议。根据DOAC的药代动力学,建议将术前无抗凝间隔时间缩短至2 - 4个半衰期(HWZ)(1 - 5天),并在术后早期重新开始用药。在这种情况下无需桥接。另一方面,一些外科医生倾向于在手术前5天尽早中断DOAC,至术后至少2天,以确保围手术期有足够的止血效果。根据血栓栓塞风险,需要进行桥接。这些建议是基于有限的临床经验且缺乏拮抗剂而提出的。

结论

凝血的围手术期管理仍然是一项挑战。虽然对于苯丙香豆素有统一的决策辅助工具,但由于数据有限,DOAC治疗下的方法仍存在争议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验